Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2015 Jan;17(1):134-40.
doi: 10.1016/j.neo.2014.12.001.

Frequence, spectrum and prognostic impact of additional malignancies in patients with gastrointestinal stromal tumors

K Kramer  1 , S Wolf  2 , B Mayer  3 , S A Schmidt  4 , A Agaimy  5 , D Henne-Bruns  6 , U Knippschild  7 , M Schwab  8 , M Schmieder  9
Affiliations
Multicenter Study

Frequence, spectrum and prognostic impact of additional malignancies in patients with gastrointestinal stromal tumors

K Kramer et al. Neoplasia. 2015 Jan.

Abstract

Currently available data on prognostic implication of additional neoplasms in GIST miss comprehensive information on patient outcome with regard to overall or disease specific and disease free survival. Registry data of GIST patients with and without additional neoplasm were compared in retrospective case series. We investigated a total of 836 patients from the multi-center Ulmer GIST registry. Additionally, a second cohort encompassing 143 consecutively recruited patients of a single oncology center were analyzed. The frequency of additional malignant neoplasms in GIST patients was 31.9% and 42.0% in both cohorts with a mean follow-up time of 54 and 65 months (median 48 and 60 months), respectively. The spectrum of additional neoplasms in both cohorts encompasses gastrointestinal tumors (43.5%), uro-genital and breast cancers (34.1%), hematological malignancies (7.3%), skin cancer (7.3%) and others. Additional neoplasms have had a significant impact on patient outcome. The five year overall survival in GIST with additional malignant neoplasms (n = 267) was 62.8% compared to 83.4% in patients without other tumors (n = 569) (P < .001, HR=0.397, 95% CI: 0.298-0.530). Five-year disease specific survival was not different between both groups (90.8% versus 90.9%). 34.2% of all deaths (n = 66 of n = 193) were GIST-related. The presented data suggest a close association between the duration of follow-up and the rate of additional malignancies in GIST patients. Moreover the data indicate a strong impact of additional malignant neoplasms in GIST on patient outcome. A comprehensive follow-up strategy of GIST patients appears to be warranted.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival in comparison of GIST patients with and without secondary malignancies.
Figure 2
Figure 2
Disease specific survival in GIST patients with and without secondary malignancy.
See this image and copyright information in PMC

References

    1. Tran T., Davila J.A., El-Serag H.B. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005;100:162–168. - PubMed
    1. Nilsson B., Bümming P., Meis-Kindblom J.M., Odén A., Dortok A., Gustavsson B. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western Sweden. Cancer. 2005;103:821–829. - PubMed
    1. Tryggvason G., Kristmundsson T., Orvar K., Jónasson J.G., Magnússon M.K., Gíslason H.G. Clinical study on gastrointestinal stromal tumors (GIST) in Iceland, 1990–2003. Dig Dis Sci. 2007;52:2249–2253. - PubMed
    1. Steigen S.E., Bjerkehagen B., Haugland H.K., Nordrum I.S., Løberg E.M., Isaksen V. Diagnostic and prognostic markers for gastrointestinal stromal tumors in Norway. Mod Pathol. 2008;21:46–53. - PubMed
    1. Cassier P.A., Ducimetière F., Lurkin A., Ranchère-Vince D., Scoazec J.-Y., Bringuier P.-P. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer. 2010;103:165–170. - PMC - PubMed

Publication types

LinkOut - more resources